Page last updated: 2024-12-06

nexopamil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Nexopamil is a calcium channel blocker that was originally developed as an antihypertensive agent. Its synthesis involves a multi-step process, starting with a substituted benzophenone derivative. Nexopamil exhibits a unique pharmacological profile, characterized by its potent inhibitory activity against L-type calcium channels in the heart, smooth muscle, and other tissues. This action contributes to its antihypertensive effects by reducing peripheral vascular resistance and slowing heart rate. However, nexopamil also exhibits antiarrhythmic properties and has been investigated for its potential therapeutic benefits in various cardiovascular conditions, including atrial fibrillation and angina pectoris. The compound's selectivity for L-type calcium channels over other ion channels, combined with its favorable pharmacokinetic properties, has spurred research into its potential applications in treating cardiovascular diseases. While nexopamil was initially marketed as an antihypertensive drug, its clinical use has declined due to its adverse effects. Nevertheless, ongoing research explores its potential in treating other cardiovascular conditions, with particular interest in its antiarrhythmic and anti-ischemic effects.'

nexopamil: RN refers to (2S)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65984
CHEMBL ID2106832
SCHEMBL ID1980872
MeSH IDM0226152

Synonyms (11)

Synonym
nexopamil
(2s)-5-[hexyl(methyl)amino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
136033-49-3
unii-eca0e1po91
nexopamil [inn]
(2s)-5-(hexylmethylamino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile
eca0e1po91 ,
CHEMBL2106832
SCHEMBL1980872
Q27277102
AKOS040749020

Research Excerpts

Treatment

ExcerptReferenceRelevance
"In nexopamil-treated pigs, this was paralleled by reduced release of creatine kinase (CK) into coronary venous blood."( Protection of reperfused ischemic pig myocardium by nexopamil, a new combined Ca2+ and serotonin antagonist.
Braun, M; Hohlfeld, T; Schrör, K; Strobach, H, 1994
)
1.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]